System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Balázs Sánta, MD is an expert in Pulmonology at Chiesi (Group) (Italy). Balázs Sánta has authored 19 publications, the most recent in 2025, and is an investigator in 2 clinical trials, 2 of them ongoing. SLR score: 75 (community average: 125). How the SLR is computed.

LeadR Profile

Balázs Sánta, MD Chiesi (Group) Italy
75 ScienceLeadR Reputation 75

Unlock

Register Login
Network Map

Pulmonology

Subspecialties: Public Health - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2021 - 2025
Source: PubMed

Chiesi (Group)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 19

Citations

Citations: 118 1st author: 3 Last author: 0 Unique author: 0

Main journals

05.01 - Airway pharmacology and treatment 3
Respir Med 3
Int J Chron Obstruct Pulmon Dis 2
10.01 - Respiratory infections and bronchiectasis 1
Allergy Asthma Clin Immunol 1

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-World Efficacy of BDP/FF/G Fixed Triple Inhalation Powder (NEXThaler) Therapy in the Treatment of Moderate to Severe COPD patients (RESPONSE Study).
PMID 41308796 — quality of life, lung, powders, respiratory tract diseases, inhalation, signs and symptoms, pulmonary disease, chronic obstructive, therapeutics		Respir Med20250
Comparison of healthcare costs of patients with COPD on maintenance inhaled therapies between 2011 and 2019 in Hungary using a nationwide database.
PMID 40323926 — comorbidity, health care costs, hospitalization, maintenance, pulmonary disease, chronic obstructive, therapeutics		PLoS One20250
Epidemiology of adult asthma within the Hungarian population between 2009 and 2019 - A retrospective financial database analysis.
PMID 40129754 — epidemiology, prescriptions, maintenance, therapeutics, asthma		Glob Epidemiol20250
Particularities of deposition of two ICS-LABA fixed dose combination dry powder aerosol drugs in the airways of COPD patients.
PMID 39701396 — lung, powders, pharmaceutical preparations, aerosols, inhalation, pulmonary disease, chronic obstructive		Respir Med20240
Analysis of COPD: Distinguishing Characteristics and Management of Smoking vs Never Smoking Patients.
PMID 39677832 — quality of life, comorbidity, lung, smokers, pulmonary disease, chronic obstructive, therapeutics, history, smoking, demography		Int J Chron Obstruct Pulmon Dis20244

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 2

By status:

Not yet recruiting 1
Recruiting 1

By type:

Observational 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 1
multicentricup10 1

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
The Importance of Tailored Education And Device Handling for Asthmatic Patients
NCT06840522 — lung, pharmaceutical preparations, inhalation, therapeutics, asthma, education		N/ANot yet recruiting2025
Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients in a Real life Setting
NCT06678191 — chronic disease, lung, glycopyrrolate, pulmonologists, inhalation, pulmonary disease, chronic obstructive, fumarates, formoterol fumarate, beclomethasone, therapeutics, asthma, lung diseases, lung diseases, obstructive		N/ARecruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS